Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma

A therapeutic dilemma

Seok Jin Kim, Sung Yong Oh, Jin Seok Kim, Hawk Kim, Gyeong Won Lee, Jong Ho Won, Ho Jin Shin, Deok Hwan Yang, Chul Won Choi, Jinny Park, Won Seog Kim, Cheolwon Suh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Secondary central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL) includes an isolated CNS relapse or CNS involvement with systemic disease progression. This rare but fatal clinical problem still remains a therapeutic dilemma in the management of DLBCL. However, there are limited data about its treatment outcome. In this study, we gathered 73 cases with secondary CNS involvement of DLBCL from 11 hospitals in Korea. The data were retrospectively compared according to the status of systemic disease (isolated vs. combined CNS involvement) and the use of high-dose methotrexate treatment (HD MTX). Twenty-nine patients showed isolated CNS involvement while 44 had combined CNS involvement with systemic relapse or progression. Thirty-three cases (45.2%) occurred within 6 months from the initial diagnosis, and the majority of these were associated with systemic disease relapse or progression (n = 27). In isolated CNS involvement, HD MTX resulted in fewer treatment failures (3/11) than the other treatments such as other salvage chemotherapy and/or radiotherapy/intraventricular chemotherapy (14/15). However, neither HD MTX nor other treatments were effective at reducing the treatment failure rate in combined CNS involvement (8/10 and 23/30, respectively). Thus, isolated CNS involvement had a better survival than combined involvement (P = 0.008), but systemic disease progression was the main cause of death in combined as well as isolated CNS involvement. In conclusion, the prognosis of secondary CNS involvement was dismal even after intensive chemotherapy using HD MTX. Further research focusing on the development of an optimal treatment strategy is warranted.

Original languageEnglish
Pages (from-to)539-546
Number of pages8
JournalAnnals of Hematology
Volume90
Issue number5
DOIs
Publication statusPublished - 2011 May 1

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Central Nervous System
Methotrexate
Therapeutics
Treatment Failure
Recurrence
Drug Therapy
Disease Progression
Korea
Cause of Death
Radiotherapy

Keywords

  • Central nervous system
  • Diffuse large B-cell lymphoma
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma : A therapeutic dilemma. / Kim, Seok Jin; Oh, Sung Yong; Kim, Jin Seok; Kim, Hawk; Lee, Gyeong Won; Won, Jong Ho; Shin, Ho Jin; Yang, Deok Hwan; Choi, Chul Won; Park, Jinny; Kim, Won Seog; Suh, Cheolwon.

In: Annals of Hematology, Vol. 90, No. 5, 01.05.2011, p. 539-546.

Research output: Contribution to journalArticle

Kim, SJ, Oh, SY, Kim, JS, Kim, H, Lee, GW, Won, JH, Shin, HJ, Yang, DH, Choi, CW, Park, J, Kim, WS & Suh, C 2011, 'Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: A therapeutic dilemma', Annals of Hematology, vol. 90, no. 5, pp. 539-546. https://doi.org/10.1007/s00277-010-1104-0
Kim, Seok Jin ; Oh, Sung Yong ; Kim, Jin Seok ; Kim, Hawk ; Lee, Gyeong Won ; Won, Jong Ho ; Shin, Ho Jin ; Yang, Deok Hwan ; Choi, Chul Won ; Park, Jinny ; Kim, Won Seog ; Suh, Cheolwon. / Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma : A therapeutic dilemma. In: Annals of Hematology. 2011 ; Vol. 90, No. 5. pp. 539-546.
@article{bb4f2bc6a40e42cf824668fdb8a089c5,
title = "Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: A therapeutic dilemma",
abstract = "Secondary central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL) includes an isolated CNS relapse or CNS involvement with systemic disease progression. This rare but fatal clinical problem still remains a therapeutic dilemma in the management of DLBCL. However, there are limited data about its treatment outcome. In this study, we gathered 73 cases with secondary CNS involvement of DLBCL from 11 hospitals in Korea. The data were retrospectively compared according to the status of systemic disease (isolated vs. combined CNS involvement) and the use of high-dose methotrexate treatment (HD MTX). Twenty-nine patients showed isolated CNS involvement while 44 had combined CNS involvement with systemic relapse or progression. Thirty-three cases (45.2{\%}) occurred within 6 months from the initial diagnosis, and the majority of these were associated with systemic disease relapse or progression (n = 27). In isolated CNS involvement, HD MTX resulted in fewer treatment failures (3/11) than the other treatments such as other salvage chemotherapy and/or radiotherapy/intraventricular chemotherapy (14/15). However, neither HD MTX nor other treatments were effective at reducing the treatment failure rate in combined CNS involvement (8/10 and 23/30, respectively). Thus, isolated CNS involvement had a better survival than combined involvement (P = 0.008), but systemic disease progression was the main cause of death in combined as well as isolated CNS involvement. In conclusion, the prognosis of secondary CNS involvement was dismal even after intensive chemotherapy using HD MTX. Further research focusing on the development of an optimal treatment strategy is warranted.",
keywords = "Central nervous system, Diffuse large B-cell lymphoma, Prognosis",
author = "Kim, {Seok Jin} and Oh, {Sung Yong} and Kim, {Jin Seok} and Hawk Kim and Lee, {Gyeong Won} and Won, {Jong Ho} and Shin, {Ho Jin} and Yang, {Deok Hwan} and Choi, {Chul Won} and Jinny Park and Kim, {Won Seog} and Cheolwon Suh",
year = "2011",
month = "5",
day = "1",
doi = "10.1007/s00277-010-1104-0",
language = "English",
volume = "90",
pages = "539--546",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma

T2 - A therapeutic dilemma

AU - Kim, Seok Jin

AU - Oh, Sung Yong

AU - Kim, Jin Seok

AU - Kim, Hawk

AU - Lee, Gyeong Won

AU - Won, Jong Ho

AU - Shin, Ho Jin

AU - Yang, Deok Hwan

AU - Choi, Chul Won

AU - Park, Jinny

AU - Kim, Won Seog

AU - Suh, Cheolwon

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Secondary central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL) includes an isolated CNS relapse or CNS involvement with systemic disease progression. This rare but fatal clinical problem still remains a therapeutic dilemma in the management of DLBCL. However, there are limited data about its treatment outcome. In this study, we gathered 73 cases with secondary CNS involvement of DLBCL from 11 hospitals in Korea. The data were retrospectively compared according to the status of systemic disease (isolated vs. combined CNS involvement) and the use of high-dose methotrexate treatment (HD MTX). Twenty-nine patients showed isolated CNS involvement while 44 had combined CNS involvement with systemic relapse or progression. Thirty-three cases (45.2%) occurred within 6 months from the initial diagnosis, and the majority of these were associated with systemic disease relapse or progression (n = 27). In isolated CNS involvement, HD MTX resulted in fewer treatment failures (3/11) than the other treatments such as other salvage chemotherapy and/or radiotherapy/intraventricular chemotherapy (14/15). However, neither HD MTX nor other treatments were effective at reducing the treatment failure rate in combined CNS involvement (8/10 and 23/30, respectively). Thus, isolated CNS involvement had a better survival than combined involvement (P = 0.008), but systemic disease progression was the main cause of death in combined as well as isolated CNS involvement. In conclusion, the prognosis of secondary CNS involvement was dismal even after intensive chemotherapy using HD MTX. Further research focusing on the development of an optimal treatment strategy is warranted.

AB - Secondary central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL) includes an isolated CNS relapse or CNS involvement with systemic disease progression. This rare but fatal clinical problem still remains a therapeutic dilemma in the management of DLBCL. However, there are limited data about its treatment outcome. In this study, we gathered 73 cases with secondary CNS involvement of DLBCL from 11 hospitals in Korea. The data were retrospectively compared according to the status of systemic disease (isolated vs. combined CNS involvement) and the use of high-dose methotrexate treatment (HD MTX). Twenty-nine patients showed isolated CNS involvement while 44 had combined CNS involvement with systemic relapse or progression. Thirty-three cases (45.2%) occurred within 6 months from the initial diagnosis, and the majority of these were associated with systemic disease relapse or progression (n = 27). In isolated CNS involvement, HD MTX resulted in fewer treatment failures (3/11) than the other treatments such as other salvage chemotherapy and/or radiotherapy/intraventricular chemotherapy (14/15). However, neither HD MTX nor other treatments were effective at reducing the treatment failure rate in combined CNS involvement (8/10 and 23/30, respectively). Thus, isolated CNS involvement had a better survival than combined involvement (P = 0.008), but systemic disease progression was the main cause of death in combined as well as isolated CNS involvement. In conclusion, the prognosis of secondary CNS involvement was dismal even after intensive chemotherapy using HD MTX. Further research focusing on the development of an optimal treatment strategy is warranted.

KW - Central nervous system

KW - Diffuse large B-cell lymphoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=79956149229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956149229&partnerID=8YFLogxK

U2 - 10.1007/s00277-010-1104-0

DO - 10.1007/s00277-010-1104-0

M3 - Article

VL - 90

SP - 539

EP - 546

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 5

ER -